DR. MARK CONNORS, M.D.
Medical Practice in Bethesda, MD
License number
Maryland MD051910L
Category
Medical Practice
Type
Pediatric Infectious Diseases
Address
Address
10 Center Dr, Bethesda, MD 20892
Phone
(301) 496-8057
Personal information
See more information about MARK CONNORS at radaris.comName
Address
Phone
6703 Kenwood Forest Ln, Chevy Chase, MD 20815
Professional information
Dr. Mark Connors, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Pediatric Infectious Disease Medicine
Address:
10 Ctr Dr SUITE 10, Bethesda 20892
Certifications:
Pediatric Infectious Disease Medicine, 2005, Pediatrics, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Temple University
Graduated: 1985
Temple University
Graduated: 1985
Immunogenic Compositions Comprising Cold-Adapted Attenuated Respiratory Syncytial Virus Mutants
US Patent:
6284254, Sep 4, 2001
Filed:
May 30, 1995
Appl. No.:
8/453304
Inventors:
Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA
Assignee:
The United States of America as represented by the Department of Health and
Human Services - Washington DC
Human Services - Washington DC
International Classification:
A61K 39155
US Classification:
4242111
Abstract:
The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and children throughout the world. RSV is a major cause of pneumonia and bronchiolitis in infants under one year of age, and is a major cause of fatal respiratory tract disease in these infants. The treatment and prevention of RSV infection has been problematic. However, the present invention addresses some of these concerns by providing attenuated RSV strains that are suitable for inclusion in immunizing compositions. Specifically, the present invention is directed toward the introduction of growth restriction mutations into incompletely attenuated host range-restricted cold-passaged respiratory syncytial virus (cpRSV) strains by further passage of the strains at increasingly reduced temperatures to produce derivative strains which are more satisfactorily attenuated. These cold-adaptation (ca) approaches were used to introduce further attenuation in the parental RSV virus cpRSV-3131, which is incompletely attenuated in seronegative children. Mutants of the parental strain were obtained by selecting for large plaque production at reduced temperatures.
Neutralizing Antibodies To Hiv-1 And Their Use
US Patent:
2012024, Sep 27, 2012
Filed:
Mar 23, 2012
Appl. No.:
13/429279
Inventors:
John R. Mascola - Rockville MD, US
Richard T. Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Vellinge, SE
Mario Roederer - Washington DC, US
Zhi-yong Yang - Potomac MD, US
Gary J. Nabel - Washington DC, US
Peter D. Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
Gilad Ofek - Washington DC, US
Lawrence Shapiro - Bethesda MD, US
Jiang Zhu - Ashburn VA, US
William R. Schief - Encinitas CA, US
Richard T. Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Vellinge, SE
Mario Roederer - Washington DC, US
Zhi-yong Yang - Potomac MD, US
Gary J. Nabel - Washington DC, US
Peter D. Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
Gilad Ofek - Washington DC, US
Lawrence Shapiro - Bethesda MD, US
Jiang Zhu - Ashburn VA, US
William R. Schief - Encinitas CA, US
International Classification:
A61K 39/395, C12N 15/63, C12N 1/21, C12N 1/19, A61P 31/18, C12N 15/74, G01N 21/64, C07K 16/10, C12N 15/13, C12N 9/96, C12N 5/10
US Classification:
4241421, 435188, 4353201, 43525233, 4352523, 43525235, 43525231, 4352542, 4353391, 435 5, 436501, 53038815, 5303873, 5303913, 536 2353
Abstract:
Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and uses of these antibodies, are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
Induction Of Proliferation, Effector Molecule Expression, And Cytolytic Capacity Of Hiv-Specific Cd8+ T Cells
US Patent:
2011005, Mar 3, 2011
Filed:
Mar 25, 2009
Appl. No.:
12/934522
Inventors:
Mark Connors - Bethesda MD, US
Stephen A. Migueles - Washington DC, US
Stephen A. Migueles - Washington DC, US
Assignee:
The United States of America, As Represented By The Secretary, Department of - Bethesda MD
International Classification:
A61K 39/21, C12N 5/078, C12N 5/0783, A61P 37/04, A61P 31/18
US Classification:
4242081, 435325, 435375
Abstract:
Provided is a method of activating an immune cell of a subject with Human Immunodeficiency Virus (HIV), comprising contacting the immune cell with a phorbol ester and a calcium ionophore. Also provided is a composition comprising immune cells of a subject diagnosed with HIV, wherein the immune cells are activated by contact with a phorbol ester and a calcium ionophore. Methods of using the disclosed compositions are also disclosed.
Neutralizing Antibodies To Hiv-1 And Their Use
US Patent:
8637036, Jan 28, 2014
Filed:
Mar 23, 2012
Appl. No.:
13/429286
Inventors:
John R. Mascola - Rockville MD, US
Richard T. Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Vellinge, SE
Mario Roederer - Washington DC, US
Zhi-yong Yang - Potomac MD, US
Gary J. Nabel - Washington DC, US
Peter D. Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
William R. Schief - Encinitas CA, US
Richard T. Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Vellinge, SE
Mario Roederer - Washington DC, US
Zhi-yong Yang - Potomac MD, US
Gary J. Nabel - Washington DC, US
Peter D. Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
William R. Schief - Encinitas CA, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
University of Washington - Seattle WA
University of Washington - Seattle WA
International Classification:
A61K 39/42, A61K 39/21, C12Q 1/70
US Classification:
4241601, 4242081, 435 5
Abstract:
Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
Attenuated Respiratory Syncytial Virus Vaccine Compositions
US Patent:
5922326, Jul 13, 1999
Filed:
Oct 21, 1994
Appl. No.:
8/327263
Inventors:
Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Assignee:
The United States of America, as represented by the Department of Health
& Human Services - Washington DC
& Human Services - Washington DC
International Classification:
A61K 39155, C12N 704, C12N 708
US Classification:
4242111
Abstract:
The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
Attenuated Respiratory Syncytial Virus Vaccine Compositions
US Patent:
5882651, Mar 16, 1999
Filed:
May 30, 1995
Appl. No.:
8/453294
Inventors:
Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA
Assignee:
United States of America - Washington DC
American Home Products Corporation - Parsippany NJ
American Home Products Corporation - Parsippany NJ
International Classification:
A61K 39155, C12N 704, C12N 706, C12N 708
US Classification:
4242111
Abstract:
The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
Neutralizing Antibodies To Hiv-1 And Their Use
US Patent:
2012028, Nov 8, 2012
Filed:
Sep 24, 2010
Appl. No.:
13/498125
Inventors:
John R. Mascola - Rockville MD, US
Richard Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Malmo, SE
Mario Roederer - Bethesda MD, US
Zhi-yong Yang - Potomac MD, US
Gary Nabel - Washington DC, US
Peter Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
Gilad Ofek - Washington DC, US
Lawrence Shapiro - Bethesda MD, US
Jiang Zhu - Bethesda MD, US
William R. Schief - Seattle WA, US
Richard Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Malmo, SE
Mario Roederer - Bethesda MD, US
Zhi-yong Yang - Potomac MD, US
Gary Nabel - Washington DC, US
Peter Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
Gilad Ofek - Washington DC, US
Lawrence Shapiro - Bethesda MD, US
Jiang Zhu - Bethesda MD, US
William R. Schief - Seattle WA, US
International Classification:
C07K 16/10, A61K 39/42, C12N 15/13, C12N 1/21, C12N 15/74, G01N 33/569, A61P 31/18, G01N 33/577, C12N 9/96, C12N 15/63
US Classification:
4241421, 53038815, 5303873, 5303913, 435188, 536 2353, 4353201, 5303894, 435 5, 436501, 43525231, 4352523, 43525235
Abstract:
Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.